Efficacy of Ursodeoxycholic Acid and Conventional Western Medicine in Treating Bile Reflux Gastritis Combined with Helicobacter Pylori Infection and Its Effect on IL-8 and PGE2

Abstract

Abstract: Objective To investigate the therapeutic effect of ursodeoxycholic acid and conventional western medicine on bile reflux gastritis (BRG) combined with Helicobacter pylori(Hp) infection and its effect on interleukin-8 (IL-8) and prostaglandin E2 (PGE2). Methods A total of 100 BRG patients with positive Helicobacter pylori respiratory test admitted in Bayannur City Hospital from May 2019 to May 2021 were selected for the study. They were randomly divided into observation group and control group, with 50 cases in each group. The control group received conventional western treatment (clarithromycin + omeprazole + amoxicillin), and the observation group added ursodeoxycholic acid therapy to conventional western treatment. The clinical efficacy of the two groups was compared. The levels of serum interleukin-8 (IL-8), prostaglandin E₂ (PGE₂), gastrin (GAS), motilin (MTL), cholecystokinin (CCK) and adverse reactions were detected by enzyme-linked immunosorbent assay before and after treatment. Results The total effective rate of the observation group was significantly higher than that of the control group (P<0.05); After treatment, the level of serum IL-8 in the two groups was lower than that in the control group, while the level of PGE₂ in the observation group was higher than that in the control group (P<0.05); After treatment, the serum CCK level of the two groups decreased, the level of MTL and GAS in the observation group was lower than that in the control group, and the level of MTL and GAS in the observation group was higher than that in the control group (P<0.05); There was no serious adverse reaction in the two groups, and there was no significant difference in the comparison of mild adverse reactions (P>0.05), but the eradication rate of Hp in the observation group was higher than that in the control group (P<0.05). Conclusion Adding ursodeoxycholic acid on the basis of conventional Western medicine can improve the clinical effect of bile reflux gastritis complicated with Hp infection, reduce the inflammatory reaction of patients, improve gastric motility, regulate gastrointestinal hormones, increase the eradication rate of Hp, and the safety of the drug is better.

Key words: ursodeoxycholic acid, bile reflux gastritis, Helicobacter pylori infection, interleukin-8, prostaglandin e₂

CLC Number:

R573.3

ZHAO Xing. Efficacy of Ursodeoxycholic Acid and Conventional Western Medicine in Treating Bile Reflux Gastritis Combined with Helicobacter Pylori Infection and Its Effect on IL-8 and PGE2[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(1): 168-171.

References

[1] 赵海燕,梁军,边巴多杰,等.高原地区胆汁反流性胃炎的临床特征及危险因素[J].西部医学,2021,33(3):406-410.
[2] 夏翔,沈艳莹,朱纯超,等.腹腔镜辅助保留幽门胃切除术改善早期胃癌术后胆汁反流性胃炎前瞻性随机对照研究[J].中国实用外科杂志,2020,40(5):557-562.
[3] 张立辉,张超,时霞,等.枳实总黄酮苷对胆汁反流性胃炎大鼠的胃黏膜保护作用[J].中国临床药理学杂志,2020,36(22):3760-3763.
[4] 李艳,张锋,周佳美.气滞胃痛颗粒联合熊去氧胆酸治疗肝胃不和型胆汁反流性胃炎疗效研究[J].陕西中医,2020,41(1):50-52.
[5] 田建宏,张雪波.奥美拉唑联合克拉霉素与甲硝唑治疗小儿幽门螺旋杆菌相关性胃炎对患儿炎症因子,免疫功能水平的影响[J].医学临床研究,2020,37(10):1545-15471551.
[6] 唐旭东,李振华,李保双,等.慢性胃炎诊疗指南[J].中国中医药现代远程教育,2011,9(10):123-125.
[7] 赵文霞. 从肝论治胆汁反流性胃炎临证探析[J].中国中西医结合消化杂志,2020,28(9):649-651.
[8] 李文娟,王君,吴永梅,等.六味安消胶囊联合熊去氧胆酸治疗胆汁反流性胃炎临床疗效及对胃内24h胆汁分泌的影响[J].湖北中医药大学学报,2020,22(1):27-30.
[9] 戴硙,姚玉玲,周莹乔.荜铃胃痛颗粒联合兰索拉唑四联方案治疗慢性胃炎合并幽门螺杆菌感染患者的疗效研究[J].现代消化及介入诊疗,2020,25(4):515-517.
[10] 汪楠,李岩.和胃反流康对胆汁反流性胃炎模型大鼠血清及胃黏膜组织白细胞介素6,白细胞介素8的含量及表达水平的影响[J].河北中医,2020,42(12):1855-1859,1865.
[11] 喻勤,彭昌能,刘浒.复方丙谷胺西咪替丁对慢性萎缩性胃炎患者胃动力水平和胃黏膜PGE2水平的影响[J].实用药物与临床,2021,24(2):1545-1547,1551.
[12] 何梦龙,霍金苑,聂韶安.熊去氧胆酸联合序贯疗法治疗胆汁反流性胃炎合并幽门螺杆菌感染的临床研究[J].临床医药实践,2022,10(31):731-733,777.
[13] 洪丽莉. 达立通颗粒对胆囊切除术后胆汁反流性胃炎患者胃动力和胃肠激素的影响[J].武警医学,2021,32(7):612-615.
[14] 冀渤海,梁靓靓.柴枳夏及汤对胆汁反流性胃炎大鼠血清及血浆中胃动素,血管活性肠肽,生长抑素表达的影响[J].陕西中医,2021,42(1):12-17.
[15] 王飞,胡方启,王乐,等.益生菌联合三联疗法治疗小儿幽门螺杆菌相关性胃炎的疗效及对炎性因子的影响[J].现代生物医学进展,2020,20(19):3797-3800.